AZ says second COVID jab dose isn’t linked to rare clot reactionA new analysis has suggested that the rare blood clot side effects linked to AstraZeneca’s COVID-19 vaccine Vaxzevria Share XAZ says second COVID jab dose isn’t linked to rare clot reactionhttps://pharmaphorum.com/news/az-says-second-covid-jab-dose-isnt-linked-to-rare-clot-reaction/
Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
Study finds jabs cut severe variant COVID disease after one shotA real-world study carried out in Canada has found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce Share XStudy finds jabs cut severe variant COVID disease after one shothttps://pharmaphorum.com/news/study-finds-jabs-cut-severe-variant-covid-disease-after-one-shot/
Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
AstraZeneca bags Imfinzi okay in big Chinese lung cancer marketChina has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the Share XAstraZeneca bags Imfinzi okay in big Chinese lung cancer markethttps://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/
FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiaSafety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for Share XFDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiahttps://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/
AZ, J&J tweaking COVID shots to reduce clotting risks; reportAstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk Share XAZ, J&J tweaking COVID shots to reduce clotting risks; reporthttps://pharmaphorum.com/news/az-jj-covid-vaccine-reduce-clotting-risks/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
